Westlake Chemical Corporation (NYSE:WLK)
Westlake Chemical Corporation (NYSE:WLK) represented a move of 0.93 percent or $-1.18 per share and closed its previous day trading session at $72.49. 1.13 Million Shares were traded in the last trading session with an Average Volume of 863.58 Million Shares. The stock currently has a Market Capitalization of 9.28 Billion.
Westlake Chemical Corporation is a vertically integrated international manufacturer and supplier of petrochemicals, polymers and fabricated products. The company’s range of products includes ethylene, polyethylene, styrene, vinyl intermediates, PVC, PVC Pipe, PVC windows, fence and decking components.
The stock traded between $ 66.91 and $124.29 over 1-Year time period showing its price to sales ratio of 1.07. Westlake Chemical Corporation (NYSE:WLK) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-5.32 and 200-Day Simple Moving Average of $-27.35. Its Price to Free Cash Flow is 9.8 and Price to Book of 1.67.
Analyst’s recommended the stock as 2.7 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Westlake Chemical Corporation (NYSE:WLK) reported its Actual EPS of $2.35/share. The analysts offering Earnings Estimates for the company were believing that Westlake Chemical Corporation could bring EPS of $2.09/share. The difference between Actual EPS and Estimated EPS was 0.26 Percent. Thus showing an Earnings Surprise of 12.4 Percent.
TG Therapeutics, Inc. (NASDAQ:TGTX)
In the last trading session, TG Therapeutics, Inc. (NASDAQ:TGTX) added its value by 0.8% closing at the price of $5.04. The stock currently has market capitalization of 414.49 Million, with average volume of 1.67 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently TG Therapeutics, Inc. (NASDAQ:TGTX) is showing beta of 1.7. This particular value of beta suggests that TG Therapeutics, Inc. (NASDAQ:TGTX) has historically moved 170% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for TG Therapeutics, Inc. (NASDAQ:TGTX) is at $-2.08.
The stock currently has RSI of 47.89. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.
TG Therapeutics, Inc. (NASDAQ:TGTX) topped its 52-week high price of $17.35 on 03/09/18 and 52-Week Low Price of $ 4.20 on 10/29/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.91% and monthly volatility of 6.54% respectively.